Individualizing cancer chemotherapy.
McLeod
Howard L
HL
Washington University, St. Louis, USA.
D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D005820:Genetic Testing / Q000379:methods / Q000639:trends; D014453:Glucuronosyltransferase / Q000235:genetics; D006801:Humans; D000077146:Irinotecan; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D009503:Neutropenia / Q000139:chemically induced / Q000201:enzymology / Q000235:genetics; D043922:Toxicogenetics / Q000379:methods / Q000639:trends
D004791:Enzyme Inhibitors; D000077146:Irinotecan; D014453:Glucuronosyltransferase; D002166:Camptothecin